open access

Vol 5, No 4 (2000)
Original papers
Published online: 2000-01-01
Submitted: 2000-11-14
Get Citation

Palliative HDR brachytherapy in treatment of advanced esophageal cancer

Janusz Skowronek, Krystyna Adamska, Magdalena Suwalska, Grzegorz Zwierzchowski
DOI: 10.1016/S1507-1367(00)70367-1
·
Rep Pract Oncol Radiother 2000;5(4):111-119.

open access

Vol 5, No 4 (2000)
Original papers
Published online: 2000-01-01
Submitted: 2000-11-14

Abstract

Introduction

Patients not qualified for surgery due to the location and clinically advanced stage of oesophageal cancer constitute a group with poor prognosis. Only few of them qualify for radical teletherapy, most of them are being treated symptomatically. The paper presents preliminary results of HDR brachytherapy applied in patients with inoperable oesophageal cancer.

Material and Methods

Between May 1999 and February 2000, 37 patients with inoperable oesophageal cancer were treated by HDR brachytherapy. The patients’ age ranged between 42 and 81 years, mean: 53.1 yr. In HDR brachytherapy the most commonly employed dose was that of 21.5 Gy (in three fractions) at the tumour site. In four cases the mediastinum was additionally irradiated with a dose of 20 Gy in five fractions, and in nine patients treated radically, teletherapy with a dose of 50–60 Gy at the vicinity of the oesophagus was used following brachytherapy. The effect of the treatment in the form of local remission and regression of dysphagia was assessed in the 1st, 3rd and 6th month of follow-up after the completion of the treatment.

Results

The mean follow-up was 6 months. Total remission, partial remission and no remission, as assessed in the 1st month after the treatment, was found in 7 (18.9%), 18 (48.6%), and 12 (32.4%) patients, respectively. After the 3- and 6-month follow-up remission was re-affirmed in two-thirds of the patients under observation. In the group of patients treated with the combination method total remission was found in two (20%) patients, whereas partial remission was ascertained in 6 (60%) patients. In four (10.8%) patients oesophageal fistula was detected during the follow-up period.

Conclusions

HDR brachytherapy was found to lead to regression of dysfagia in a significant number of patients with inoperable oesophageal cancer. In some patients total remission was achieved lasting more than six months. Tolerance for the treatment was good, and the number of complications did not differ from that reported by other authors.

Abstract

Introduction

Patients not qualified for surgery due to the location and clinically advanced stage of oesophageal cancer constitute a group with poor prognosis. Only few of them qualify for radical teletherapy, most of them are being treated symptomatically. The paper presents preliminary results of HDR brachytherapy applied in patients with inoperable oesophageal cancer.

Material and Methods

Between May 1999 and February 2000, 37 patients with inoperable oesophageal cancer were treated by HDR brachytherapy. The patients’ age ranged between 42 and 81 years, mean: 53.1 yr. In HDR brachytherapy the most commonly employed dose was that of 21.5 Gy (in three fractions) at the tumour site. In four cases the mediastinum was additionally irradiated with a dose of 20 Gy in five fractions, and in nine patients treated radically, teletherapy with a dose of 50–60 Gy at the vicinity of the oesophagus was used following brachytherapy. The effect of the treatment in the form of local remission and regression of dysphagia was assessed in the 1st, 3rd and 6th month of follow-up after the completion of the treatment.

Results

The mean follow-up was 6 months. Total remission, partial remission and no remission, as assessed in the 1st month after the treatment, was found in 7 (18.9%), 18 (48.6%), and 12 (32.4%) patients, respectively. After the 3- and 6-month follow-up remission was re-affirmed in two-thirds of the patients under observation. In the group of patients treated with the combination method total remission was found in two (20%) patients, whereas partial remission was ascertained in 6 (60%) patients. In four (10.8%) patients oesophageal fistula was detected during the follow-up period.

Conclusions

HDR brachytherapy was found to lead to regression of dysfagia in a significant number of patients with inoperable oesophageal cancer. In some patients total remission was achieved lasting more than six months. Tolerance for the treatment was good, and the number of complications did not differ from that reported by other authors.

Get Citation

Keywords

advanced oesophageal cancer; HDR brachytherapy

About this article
Title

Palliative HDR brachytherapy in treatment of advanced esophageal cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 5, No 4 (2000)

Pages

111-119

Published online

2000-01-01

DOI

10.1016/S1507-1367(00)70367-1

Bibliographic record

Rep Pract Oncol Radiother 2000;5(4):111-119.

Keywords

advanced oesophageal cancer
HDR brachytherapy

Authors

Janusz Skowronek
Krystyna Adamska
Magdalena Suwalska
Grzegorz Zwierzchowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl